Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Monday, September 10, 2018
Novartis and Mundipharma, have signed an agreement for the marketing, sales and distribution of well-known pain medicine brands Voltaren and Cataflam in Malaysia, Thailand, and the Philippines.
read more
TriNetX has announced the signing of a collaboration agreement with Novartis to optimize clinical trial design and advance clinical research for Novartis programs.
read more
Thursday, November 01, 2012
Novartis announced today the construction of a new state-of-the-art biotechnology production site in Singapore with an investment valued at over USD 500 million. The new facility will focus on drug substance manufacturing based on cell culture ...
read more
Wednesday, February 03, 2021
Novartis has signed an initial agreement to leverage its manufacturing capacity and capabilities in order to address the COVID-19 pandemic by supporting the production of the Pfizer-BioNTech COVID-19 Vaccine.
read more
Novartis will highlight the strength of its expanded oncology portfolio in 21 medicines and 11 investigational compounds across more than 185 data presentations at the upcoming American Society of Clinical Oncology (ASCO) Annual Meeting, May 29-June ...
read more
Novartis announced its commitment to donate up to 130 million doses of generic hydroxychloroquine to support the global COVID-19 pandemic response.
read more
Wednesday, April 03, 2019
Novartis has entered into an agreement and plan of merger with AveXis to acquire the US-based clinical stage gene therapy company for $218 per share or a total of $8.7 billion in cash.
read more
Novartis is suing Regeneron for patent infringement over the manufacturing process used to produce its Eylea and Zaltrap eye treatments.
read more
Novartis has announced a swap of clinical assets for equity with Mereo BioPharma Group Ltd.
read more
Wednesday, September 02, 2015
Novartis has entered into a global collaboration with Amgen to commercialize and develop pioneering neuroscience treatments.
read more
Novartis is adding to its diverse and deep immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology. The agreement gives Novartis access to four pre-clinical programs that target regulatory T cell ...
read more
The Novartis Foundation and its partners have begun screening patients in the Community-based Hypertension Improvement Project (ComHIP), a two-year program designed to evaluate the impact of an innovative healthcare model on hypertension management ...
read more
Wednesday, March 07, 2018
Novartis announced an additional strategic alliance with Science 37 to initiate up to 10 new clinical trials over the next three years.
read more
Thursday, December 20, 2018
Novartis has announced an offer to acquire CellforCure from LFB.
read more
Novartis announced Shannon Thyme Klinger, Chief Legal Officer, has decided to resign from Novartis and return to the US to take an executive role at a biotechnology company.
read more